

# **INFORMATION DISCLOSURE STATEMENT**

Applicants:	Wenyuan Shi, et al.
Application No.	new
Filed:	Herewith
For:	ANTI-MICROBIAL TARGETING CHIMERIC PHARMACEUTICAL
Group Art Unit:	Unknown
Examiner:	Unknown
Attorney Docket No.:	2101363-991201

PTO  
JCS996 U.S. PAT.  
10/077524  
02/14/02

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

In accordance with the provisions of 37 C.F.R. § 1.56(a) and 37 C.F.R. § 1.97, Applicant(s) hereby make of record the references listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application.

This Information Disclosure Statement:

- (a) ☒ accompanies a new patent application submitted herewith.
- (b) ☐ is filed within three (3) months of the Filing Date or before the mailing date of a First Office Action on the merits; **OR**
- (c) ☐ after the period defined in (b) but before the mailing date of a Final Rejection or Notice of Allowance, **OR**
- (d) ☐ is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned prior to the mailing date of either a final rejection or a notice of allowance, and is accompanied by either the fee (\$180) set forth in 37 CFR § 1.17(p) or a certification as specified in 37 CFR § 1.97(e), as checked below **OR**
- (e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, and the issue fee has not been paid, and is accompanied by the requisite petition fee (\$130) set forth in 37 CFR § 1.17(l)(1) and a certification as specified in 37 CFR § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the information disclosure statement.

As required under § 1.97(e), Applicants, through the undersigned, hereby state either that:

- (f) ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or
- (g) ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

It is respectfully requested that each of the references shown on the attached Form PTO-1449 be made of record in this application. Because each of the cited references were cited in parent Application No. 09/910,358, filed July 19, 2001 none of the cited references are enclosed.

Page 1 of 2

The Commissioner is authorized to charge any deficiencies and credit any overpayment of fees

The Commissioner is authorized to charge any deficiencies and credit any overpayment of fees to our Deposit Account No. 07-1896

Date:

2/14/02

Respectfully submitted,

GRAY CARY WARE & FREIDENRICH LLP

By:

Nan Wu

Reg. No. 43,360

Attorneys for Applicant(s)

139 Townsend Street, Suite 400

San Francisco, CA 94107-1922

(415) 836-2500

☒ Customer Number or Bar Code Label

**29585**

(Insert Customer No. or Attach bar code label here)

Page 2 of 2

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Docket Number  
2101363-991201Application Number  
NewApplicant  
Wenyuan Shi, et al.Filing Date  
HerewithGroup Art Unit  
Unknown**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5	0	5	7	3	1	3	10-15-91	Lisa B. Shih, et al.	424	1.53	08-23-88
	5	7	2	6	2	9	3	03-10-98	Brian Seed	530	413	05-27-94
	4	6	7	1	9	5	8	06-09-87	John D. Rodwell	424	1.53	03-09-82
	5	9	1	0	5	7	3	06-08-99	Andreas Pluckthun et al.	530	387.3	07-22-94
	5	9	8	1	7	2	6	11-09-99	Ira Pastan	536	23.53	10-28-94
	5	6	4	6	1	1	9	07-08-97	Frank G. Oppenheim et al.	514	12	07-07-95
	5	8	5	1	5	2	7	12-22-98	Hans Hansen	424	178.1	05-19-95
	5	6	4	5	8	3	5	07-08-97	Henry Fell, Jr., et al.	424	134.1	05-23-94
	6	1	9	7	2	9	9	03-06-01	Mikael Dohlsten et al.	424	183.1	09-16-98
	5	6	7	2	3	5	1	09-30-97	Michael Chikindas et al.	424	401	12-11-95
	6	1	8	3	7	4	4	02-06-01	David M. Goldenberg	424	141.1	03-12-98

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

	SUE M. TRAVIS, et al., Bactericidal Activity of Mammalian Cathelicidin-Derived Peptides, Infection and Immunity, Vol. 68 No. 5:2748-2755, American Society for Microbiology, May 2000 (United States).
	JENS-M. SCHRODER, Commentary: Epithelial Peptide Anti-Biotics, Biochemical Pharmacology, Vol. 57, pp. 121-134, 1999, Elsevier Science.
	MANUEL L. PENICHET et al., Antibody-Cytokine Fusion Proteins For the Therapy Of Cancer, Journal of Immunological Methods, Vol. 248:91-1001 (2000), Elsevier Science B.V.
	PENG LI et al., An Antimicrobial Peptide Gene Found in the Male Reproductive System Of Rats, Science Vol. 291:1783-1785.
	SHERIE L. MORRISON et al., Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains, Proceedings Of The National Academy Of Sciences U.S.A. Vol. 81:6851-6855 (1984).
	STEVEN A. MARSHALL et al., Spectrum and Antimicrobial Activity of Alexomycin: (PNU-82, 127), A Peptide Compound Projected for Use in Animal Health, Diagnostic Microbiology, Infectious Diseases Vol. 33: 181-186 (1999), Elsevier Science, Inc. U.S.A.
	KENNETH T. MIYASAKI et al., "3-Sheet Antibiotic Peptides As Potential Dental Therapeutics, International Journal Of Antimicrobial Agents, Vol. 9:269-280 (1988), Elsevier Science, B.V.
	EVA J. HELMEHORST et al., Biochemical Journal, Vol. 326:39-45 (1997), Great Britain
	ANDREA GIACOMETTI et al., "Antimicrobial Activity Of Polycationic Peptides," Vol. 20:1265-1273 (1999), Elsevier Science, Inc.
	KATE FORTNEY et al., <i>Haemophilus ducreyi</i> Is Susceptible to Protegrin, Antimicrobia Agents and Chemotherapy, Vol. 42:2690-2693 (1998).

EXAMINER

DATE CONSIDERED

